Intima Bioscience, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
CISH Inactivated TILs in the Treatment of NSCLC
Phase 1
Not yet recruiting
- Conditions
- Metastatic Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerSquamous Cell Lung CancerCarcinoma, Non-Small-Cell LungAdenocarcinoma of LungLarge Cell Lung Cancer
- Interventions
- Drug: FludarabineDrug: CyclophosphamideBiological: CISH Inactivated TILDrug: AldesleukinDrug: Pembrolizumab
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Intima Bioscience, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05566223
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Phase 1
Recruiting
- Conditions
- Cancer, GastrointestinalGall Bladder CancerStomach CancerGastrointestinal Epithelial CancerGastrointestinal NeoplasmsCancer of Gastrointestinal TractGastrointestinal CancerPancreatic CancerColo-rectal CancerColon Cancer
- Interventions
- Drug: CyclophosphamideDrug: FludarabineBiological: Tumor-Infiltrating Lymphocytes (TIL)Drug: Aldesleukin
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Intima Bioscience, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04426669
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath